Lipoprotein (a) and long-term outcome in patients with peripheral artery disease undergoing revascularization
Open Access
- 13 October 2022
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 363, 94-101
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin CNew England Journal of Medicine, 2012
- Associations Between Lipoprotein(a) Levels and Cardiovascular Outcomes in Black and White SubjectsCirculation, 2012
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular MortalityJAMA, 2009
- Symptomatic Peripheral Arterial Disease in WomenCirculation, 2008
- Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular OutcomesArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery StudyEuropean Heart Journal, 2007
- Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- Apolipoprotein(a) Size and Lipoprotein(a) Concentration and Future Risk of Angina Pectoris with Evidence of Severe Coronary Atherosclerosis in Men: The Physicians’ Health StudyClinical Chemistry, 2004
- Edinburgh Artery Study: Prevalence of Asymptomatic and Symptomatic Peripheral Arterial Disease in the General PopulationInternational Journal of Epidemiology, 1991